No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LTRN Lantern Pharma
- 4.620
- +0.210+4.76%
Close Jul 22 16:00 ET
- 4.500
- -0.120-2.60%
Post 16:27 ET
49.71MMarket Cap-2851P/E (TTM)
4.660High4.380Low37.44KVolume4.490Open4.410Pre Close167.80KTurnover0.47%Turnover RatioLossP/E (Static)10.76MShares11.99052wk High1.39P/B36.67MFloat Cap2.38052wk Low--Dividend TTM7.94MShs Float24.840Historical High--Div YieldTTM6.35%Amplitude2.380Historical Low4.481Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Express News | Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification With Drug Candidate LP-184
Express News | Lantern Estimates That LP-284 Can Have The Potential To Improve Outcomes For 40,000 To 80,000 Patients With Blood Cancers Annually, With A Global Annual Market Potential Of $4B
Express News | Lantern Pharma Announced That The Japan Patent Office Has Issued A Certificate Of Patent For Composition Of Matter Covering Drug Candidate LP-284
Express News | Lantern Pharma Receives Certificate of Patent From Japanese Patent Office (Jpo) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma(LTRN.US) 10% Shareholder Sells US$189.1K in Common Stock
$Lantern Pharma(LTRN.US)$ 10% Shareholder Fletcher Aaron G.L. sold 30,000 shares of common stock on May 23, 24, 2024 at an average price of $6.3 for a total value of $189.1K. This transaction involves
Comments
$Lantern Pharma(LTRN.US$
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...
$Lantern Pharma(LTRN.US$
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
1
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration $Lantern Pharma(LTRN.US$
$Lantern Pharma(LTRN.US$
NEWS
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
NEWS
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
3
$Lantern Pharma(LTRN.US$
NEWS
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
NEWS
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg